论文部分内容阅读
冠状动脉介入支架术后病人常规抗血小板的治疗,目前阿司匹林与氯吡格雷联合运用已成为支架术后抗血小板的常规诊疗方法。氯吡格雷需经CYP2C19代谢生成活性产物而发挥抗血小板聚集作用。但由于氯吡格雷抵抗发生支架内血栓事件逐渐增多,这一现象也受到人们的关注,冠状动脉介入支架术后病人服用氯吡格雷支架内血栓发生率与CYP2C19基因多态性是否有相关性。现就其研究现状做一综述。
Coronary artery stenting patients after conventional antiplatelet therapy, the current use of aspirin and clopidogrel has become a common anti-platelet after stent treatment. Clopidogrel required CYP2C19 metabolism generated by the active product and exert anti-platelet aggregation. However, due to clopidogrel resistance increased incidence of stent thrombosis, this phenomenon has also been the subject of attention, coronary intervention patients with clopidogrel stent thrombosis and CYP2C19 gene polymorphism whether there is a correlation. Now on its research status to be reviewed.